- Dosing of patients with locally advanced or metastatic solid tumors has commenced in the DRAGON Phase 1 clinical trial of SRK-181, a highly specific inhibitor of latent TGFβ1 activation - Update on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results